SUMMARYAim: To compare standard and maximum daily doses of polyethylene glycol 3350 plus electrolytes (Transipeg) and polyethylene glycol 4000 (Forlax) in a multicentre, double-blind, randomized, parallel-group study. Methods: Ambulatory patients with idiopathic chronic constipation were randomized to receive Forlax (10 or 20 g) or Transipeg (5.9 or 11.8 g) for 1 month. The primary efficacy end-point was stool frequency. Secondary efficacy parameters included stool consistency, date of occurrence of first motion, straining on defecation, rectal evacuation, abdominal pain and distension. Adverse events were recorded. Results: Stool frequency was significantly increased compared with baseline in all treatment groups (P ¼ 0.0001). Most patients ( ‡ 67.3%) had their first stool within 1 day of starting treatment. Stool consistency significantly improved compared with baseline in all treatment groups (P ¼ 0.0001). The percentage of patients with normal stool consistency was significantly higher for standard-dose Transipeg vs. both maximumdose treatments (P < 0.01). Other secondary parameters were also significantly improved compared with baseline in all treatment groups (P ¼ 0.0001). All medications were well tolerated. Conclusions: Standard-dose Transipeg (5.9 g) normalized stool consistency with less semi-liquid or liquid stools than maximum-dose Transipeg and Forlax, with a non-significant trend towards less semi-liquid or liquid stools than standard-dose Forlax.
The aim of this study was to determine the craniofacial parameters in the population of the central part of Serbia. The research was conducted on 700 persons (360 males and 340 females), aged 18-65 years, selected randomly. The measured parameters were morphological facial height and breadth. The standard spreading caliper with scale was used for the measurement of facial parameters. There were significant differences in the facial parameters of male compared to female subjects in all observed parameters. The mean value of the morphological facial height in the study population was 116.8 mm ± 7.28, maximum facial breadth 124.12 mm ± 8.44, while the mean value of the total facial index was 93.68 ± 6.86. The total facial index was calculated according to the formula and the obtained results were analyzed statistically using the t-test. The dominant phenotype in the studied population was leptoprosopic. The data obtained in our study may be useful in anthropological research, forensics, genetic research, as well as in medical clinical practice
Nonprescription doses of naproxen sodium, acetaminophen, and placebo were compared to determine their efficacy and safety in osteoarthritis of the knee. In two identical multicenter, randomized, double-blind, placebo-controlled, multidose, parallel-design studies, patients with osteoarthritis aged (mean +/- SD) 60.6 +/- 12.8 years were randomized to daily doses of 660 mg naproxen sodium (440 mg naproxen sodium in patients >or=65 years), 4000 mg acetaminophen, or placebo for 7 days. Naproxen sodium (440/660 mg) provided significantly greater improvements in pain at rest, on passive motion, on weight-bearing, stiffness after rest (morning), day and night pain compared with placebo, and significantly greater relief from resting pain than acetaminophen (P < 0.05). Acetaminophen provided significantly greater improvements in day pain compared with placebo. Daily evaluations showed naproxen sodium (440/660 mg) provided superior pain relief to acetaminophen and was significantly better than acetaminophen at reducing difficulties experienced in walking several blocks and difficulties in bending, lifting, and stooping. Naproxen sodium (440/660 mg) and acetaminophen (4000 mg) were significantly more effective than placebo in improving mobility level, household tasks, and walking and bending. Patient and investigator evaluation scores were significantly higher in naproxen sodium and acetaminophen groups compared with placebo; no differences were observed between active treatments. Naproxen sodium and acetaminophen had similar safety profiles to placebo. Nonprescription doses of naproxen sodium (440/660 mg) effectively relieve pain and other symptoms of osteoarthritis. Naproxen sodium is an alternative in the initial treatment of osteoarthritis and may be preferred to acetaminophen as first-line therapy in patients with moderate or severe pain.
The aim of this study was to detect and describe the existence and incidence
of anatomical variations of the celiac trunk and superior mesenteric artery.
The study was conducted on 150 persons, who underwent abdominal Multi-
Detector Computer Tomography (MDCT) angiography, from April 2010 until
November 2012. CT images were obtained with a 64-row MDCT scanner in order to
analyze the vascular anatomy and anatomical variations of the celiac trunk
and superior mesenteric artery. In our study, we found that 78% of patients
have a classic anatomy of the celiac trunk and superior mesenteric artery.
The most frequent variation was the origin of the common hepatic artery from
the superior mesenteric artery (10%). The next variation, according to
frequency, was the origin of the left gastric artery direct from the
abdominal aorta (4%). The arc of Buhler as an anastomosis between the celiac
trunk and superior mesenteric artery, was detected in 3% of cases, as was the
presence of a common trunk of the celiac trunk and superior mesenteric artery
(in 3% of cases). Separate origin of the splenic artery and the common
hepatic artery was present in 2% of patients. The MDCT scanner gives us an
insight into normal anatomy and variations of the abdominal blood vessels,
which is very important in the planning of surgical interventions, especially
transplantation, as well as in the prevention of complications due to
ischemia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.